11 COMMERCE DRIVE, CRANFORD, NJ
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Strong Commercial Momentum for its Cancer Treatment
Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals Enters Third Amendment to Promissory Note
Ships First International Order of LYMPHIR™ to Europe
Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Elects Seven Directors at 2026 Annual Meeting
Q2
Q1
Amended Annual Report
FY 2025
Q3
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement